Cargando…

Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan

OBJECTIVE: The real-world INFORM study analyzed sociodemographics, treatment patterns and clinical outcomes for patients with newly diagnosed advanced epithelial ovarian cancer (EOC) in Australia, South Korea (S.Korea) and Taiwan preceding incorporation of poly(ADP-ribose) polymerase inhibitors into...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Hung-Hsueh, Fereday, Sian, DeFazio, Anna, Chang, Chih-Long, Bowtell, David, Hsu, Heng-Cheng, Traficante, Nadia, Jeong, Soo Young, Cheng, Wen-Fang, Ariyarantne, Dinuka, Tung, Teresa, Rajadhyaksha, Viraj, Lee, Won-Hee, Brown, David, Kim, Byoung-Gie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807365/
https://www.ncbi.nlm.nih.gov/pubmed/36366810
http://dx.doi.org/10.3802/jgo.2023.34.e3
_version_ 1784862706841419776
author Chou, Hung-Hsueh
Fereday, Sian
DeFazio, Anna
Chang, Chih-Long
Bowtell, David
Hsu, Heng-Cheng
Traficante, Nadia
Jeong, Soo Young
Cheng, Wen-Fang
Ariyarantne, Dinuka
Tung, Teresa
Rajadhyaksha, Viraj
Lee, Won-Hee
Brown, David
Kim, Byoung-Gie
author_facet Chou, Hung-Hsueh
Fereday, Sian
DeFazio, Anna
Chang, Chih-Long
Bowtell, David
Hsu, Heng-Cheng
Traficante, Nadia
Jeong, Soo Young
Cheng, Wen-Fang
Ariyarantne, Dinuka
Tung, Teresa
Rajadhyaksha, Viraj
Lee, Won-Hee
Brown, David
Kim, Byoung-Gie
author_sort Chou, Hung-Hsueh
collection PubMed
description OBJECTIVE: The real-world INFORM study analyzed sociodemographics, treatment patterns and clinical outcomes for patients with newly diagnosed advanced epithelial ovarian cancer (EOC) in Australia, South Korea (S.Korea) and Taiwan preceding incorporation of poly(ADP-ribose) polymerase inhibitors into clinical practice. METHODS: Retrospective data from patients diagnosed with EOC (high-grade serous EOC for Taiwan) between January 2014 and December 2018 with ≥12 months follow-up from diagnosis were analyzed descriptively. Survival was evaluated by Kaplan-Meier with two-sided 95% confidence interval (CI). RESULTS: Of the 987 patients (Australia, 223; S.Korea, 513; Taiwan, 251), 98% received platinum-based chemotherapy (CT). In S.Korea and Taiwan 76.0% and 78.9% respectively underwent primary cytoreductive surgery; in Australia, 56.5% had interval debulking surgery. Bevacizumab was included in primary/maintenance therapy for 22.4%, 14.6% and 6.8% of patients in Australia, S.Korea and Taiwan, respectively. Patients receiving bevacizumab were high-risk (reimbursement policy) and achieved similar real-world progression-free survival (PFS) compared with CT only. Overall, the median real-world PFS (months; 95% CI) was similar across Australia (16.0 [14.63–18.08]), S.Korea (17.7 [16.18–19.27]) and Taiwan (19.1 [17.56–22.29]). CONCLUSION: This study reveals poor prognosis despite differences in demographics and treatment patterns for patients with EOC across Asia-Pacific suggesting the need for biomarker-driven novel therapies to improve outcomes.
format Online
Article
Text
id pubmed-9807365
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
record_format MEDLINE/PubMed
spelling pubmed-98073652023-01-06 Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan Chou, Hung-Hsueh Fereday, Sian DeFazio, Anna Chang, Chih-Long Bowtell, David Hsu, Heng-Cheng Traficante, Nadia Jeong, Soo Young Cheng, Wen-Fang Ariyarantne, Dinuka Tung, Teresa Rajadhyaksha, Viraj Lee, Won-Hee Brown, David Kim, Byoung-Gie J Gynecol Oncol Original Article OBJECTIVE: The real-world INFORM study analyzed sociodemographics, treatment patterns and clinical outcomes for patients with newly diagnosed advanced epithelial ovarian cancer (EOC) in Australia, South Korea (S.Korea) and Taiwan preceding incorporation of poly(ADP-ribose) polymerase inhibitors into clinical practice. METHODS: Retrospective data from patients diagnosed with EOC (high-grade serous EOC for Taiwan) between January 2014 and December 2018 with ≥12 months follow-up from diagnosis were analyzed descriptively. Survival was evaluated by Kaplan-Meier with two-sided 95% confidence interval (CI). RESULTS: Of the 987 patients (Australia, 223; S.Korea, 513; Taiwan, 251), 98% received platinum-based chemotherapy (CT). In S.Korea and Taiwan 76.0% and 78.9% respectively underwent primary cytoreductive surgery; in Australia, 56.5% had interval debulking surgery. Bevacizumab was included in primary/maintenance therapy for 22.4%, 14.6% and 6.8% of patients in Australia, S.Korea and Taiwan, respectively. Patients receiving bevacizumab were high-risk (reimbursement policy) and achieved similar real-world progression-free survival (PFS) compared with CT only. Overall, the median real-world PFS (months; 95% CI) was similar across Australia (16.0 [14.63–18.08]), S.Korea (17.7 [16.18–19.27]) and Taiwan (19.1 [17.56–22.29]). CONCLUSION: This study reveals poor prognosis despite differences in demographics and treatment patterns for patients with EOC across Asia-Pacific suggesting the need for biomarker-driven novel therapies to improve outcomes. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2022-10-05 /pmc/articles/PMC9807365/ /pubmed/36366810 http://dx.doi.org/10.3802/jgo.2023.34.e3 Text en © 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Chou, Hung-Hsueh
Fereday, Sian
DeFazio, Anna
Chang, Chih-Long
Bowtell, David
Hsu, Heng-Cheng
Traficante, Nadia
Jeong, Soo Young
Cheng, Wen-Fang
Ariyarantne, Dinuka
Tung, Teresa
Rajadhyaksha, Viraj
Lee, Won-Hee
Brown, David
Kim, Byoung-Gie
Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan
title Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan
title_full Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan
title_fullStr Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan
title_full_unstemmed Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan
title_short Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan
title_sort contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in australia, south korea and taiwan
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807365/
https://www.ncbi.nlm.nih.gov/pubmed/36366810
http://dx.doi.org/10.3802/jgo.2023.34.e3
work_keys_str_mv AT chouhunghsueh contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT feredaysian contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT defazioanna contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT changchihlong contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT bowtelldavid contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT hsuhengcheng contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT traficantenadia contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT jeongsooyoung contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT chengwenfang contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT ariyarantnedinuka contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT tungteresa contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT rajadhyakshaviraj contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT leewonhee contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT browndavid contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan
AT kimbyounggie contrastingclinicalcharacteristicsandtreatmentpatternsinwomenwithnewlydiagnosedadvancedstageepithelialovariancancerinaustraliasouthkoreaandtaiwan